Jiangzhong Pharmaceutical Unveils Q1 2025 Financial Highlights

Get ahead of the market:

• Find top-performing stocks and invest more intelligently with Top Smart Score Stocks.
• Use filters, conduct analysis, and optimize your search for investment opportunities utilizing this tool. Cryptonesia' Stock Screener.

China Resources Pharmaceutical Group Co., Ltd. ( (HK:3320) ) has issued an update.

Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a slight decrease in revenue but an increase in net profit compared to the previous year. The financial report highlights a net increase in cash and cash equivalents, along with a rise in total assets and owner’s equity, indicating a strong financial position despite the revenue dip. Stakeholders are advised to exercise caution as the financials are unaudited and may be subject to adjustments.

Further details on China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. functions within the pharmaceutical sector, concentrating on manufacturing and distributing medicinal goods. The firm has a substantial stake in Jiangzhong Pharmaceutical—a corporation listed on the Shanghai Stock Exchange—which is an important entity in China’s pharmaceutical arena.

YTD Price Performance: -19.26%

Average Trading Volume: 1,550

Technical Sentiment Signal: Buy

Current Market Cap: €3.5B

Explore additional details about 3320 stock here. Cryptonesia’ Stock Analysis page .

Disclaimer & Disclosure Report an Issue

Trending Articles

• Everyone's Focused on AMD Shares Before Q1 Earnings Release — Christopher Rolland Sets the Scene
• 'Top Investor Calls Archer Aviation Stock a Fascinating Bet,' Reports Say
• Tesla Shares Recover: Find Out What This Leading Investor Foresees Next

Share this post